MedTrace Logo

Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid Arthritis

NCT00969527 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2011-05-09

No results posted yet for this study

Summary

The purpose of the study is to assess the efficacy of Oncoxin+Viusid administration in the treatment of rheumatoid arthritis. The duration of this double-blind placebo controlled phase 3 clinical trial will be 12 weeks. The estimated number of persons with rheumatoid arthritis to be recruited and randomized for the study is 86. The primary outcome measure: DAS28 score will be assessed at the end of the study.

Conditions

Interventions

DIETARY_SUPPLEMENT

Oncoxin + Viusid

50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.

DIETARY_SUPPLEMENT

Placebo

50 ml of Placebo (orally administered) twice a day, for 12 weeks.

Sponsors & Collaborators

  • Catalysis SL

    lead INDUSTRY

Principal Investigators

  • Juan Carlos Delgado Morales, MD · "Fructuoso Rodríguez" Orthopedic Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-03-31
Completion
2011-04-30

Countries

  • Cuba

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00969527 on ClinicalTrials.gov